Medine.co.uk

Eurax Hc Cream

Document: spc-doc_PL 44673-0104 change

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Eurax Hc Cream.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredients:    Crotamiton 10.0% w/w

Hydrocortisone 0.25% w/w

For excipients, see section 6.1

3 PHARMACEUTICAL FORM

Cream

A white to cream coloured cream

4    CLINICAL PARTICULARS

4.1    Therapeutic indications

Relief of inflammation and pruritus associated with:

Irritant contact dermatitis Allergic contact dermatitis Insect bite reactions Mild to moderate eczema

4.2 Posology and method of administration

Adults

Apply sparingly over a small area twice a day for a maximum period of 1 week. Occlusive dressings should not be used.

Paediatric population:

Eurax Hc Cream can be used in children over 10 years of age and applied as described for adults.

Do not use in children under 10 years of age except under medical supervision.

Method of administration: For cutaneous use.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients (see section 6.1, List of excipients). Bacterial, viral or fungal infections of the skin. Acute exudative dermatoses. Application to ulcerated areas.

4.4 Special warnings and precautions for use

Eurax Hc is indicated for external use only.

Do not use in children under 10 years of age except under medical supervision. Occlusive dressings should not be used.

Eurax Hc should not be used in buccal mucosa or other mucous membranes or in or around the eyes since contact with the eyelids may give rise to conjunctival inflammation. In case of accidental contact with the eyes, or mucosa rinse thoroughly with running water.

Eurax Hc should not be applied in the presence of exudative wounds, broken skin, or very inflamed skin.

Eurax Hc Cream contains propylene glycol which may cause skin irritation, stearyl alcohol which may cause local skin reactions (e.g. contact dermatitis); propyl hydroxybenzoate and methyl hydroxybenzoate which which may cause allergic reactions (possibly delayed).

4.5    Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6    Fertility, Pregnancy and lactation

Pregnancy

There are no controlled studies of Eurax Hc Cream in human pregnancy. Administration of corticosteroids to pregnant animals can cause abnormalities of foetal development. Therefore Eurax Hc Cream is not recommended during pregnancy, especially in the first three months.

Breastfeeding

It is not known whether the active substances of Eurax Hc Cream and/or their metabolite(s) pass into the breast milk after topical administration. Therefore mothers should not use Eurax Hc Cream whilst breastfeeding unless under medical supervision.

4.7 Effects on ability to drive and use machines

Eurax Hc Cream has no influence on the ability to drive and use machines.

4.8 Undesirable effects

Adverse reactions are listed below by frequency. Frequencies are defined as: uncommon (>1/1,000 to < 1/100), rare (> 1/10,000 to < 1/1,000) and very rare (<1/10,000).

Skin and subcutaneous tissue disorders:

Uncommon: pruritus

Rare: contact dermatitis, hypersensitivity (including/like rash, eczema, erythema, skin irritation, angioedema)

Treatment should be discontinued if severe irritation occurs.

In case of longer lasting administration skin atrophy, telangiectasia, striae, steroid

induced acne, peroral dermatitis and hypertrichosis cannot be excluded.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is

important. It allows continued monitoring of the benefit/risk balance of the medicinal

product. Healthcare professionals are asked to report any suspected adverse reactions

via the Y ellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9 Overdose Symptoms

In cases of accidental ingestion, acute intoxication symptoms may be observed such as nausea, vomiting and irritation of the buccal, oesophageal and gastric mucosa. Rare cases of loss of consciousness and seizure were reported. General measures to eliminate the drug and reduce its absorption should be undertaken.

Although very rare, risk of methaemoglobinaemia exists in case of accidental ingestion as well as in case of excessive cutaneous absorption.

Management

The symptoms usually disappear following the discontinuation of the drug, but in severe cases treatment with methylene blue may be considered.

5    PHARMACOLOGICAL PROPERTIES

5.1    Pharmacodynamic properties

Pharmacotherapeutic group: other antipruritics (ATC code D04AX).

Eurax Hc Cream combines the antipruritic action of crotamiton with the antiinflammatory and anti-allergic properties of hydrocortisone.

Crotamiton is effective against various forms of pruritus. The relief it affords sets in rapidly and lasts about 6 to 10 hours. By relieving the itching, Eurax Hc Cream prevents irritation of the skin caused by scratching and thus reduces the risk of secondary infection.

Hydrocortisone is a mild glucocorticoid with an anti-inflammatory, anti-allergic, and vasoconstrictive effect.

In inflammatory skin diseases of widely varying type and origin, it affords prompt relief and eliminates symptoms such as pruritus.

5.2    Pharmacokinetic properties

No pharmacokinetic data on Eurax Hc Cream are available.

5.3 Preclinical safety data

No preclinical studies were performed using Eurax Hc Cream. Preclinical data do not show teratogenic nor genotoxic risk for crotamiton. Abnormalities of foetal development were observed following administration of corticosteroids to pregnant animals. Eurax Cream, a crotamiton containing cream, administered topically once daily for 3 months to rabbits was tolerated at doses of up to 200 mg/kg without signs of toxicity, apart from transient skin irritation. No sensitising or photo-sensitising potential has been observed in animal studies.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Stearyl alcohol

White soft paraffin Polyoxyl 40 stearate Propyl hydroxybenzoate Propylene glycol Methyl hydroxybenzoate Perfume Givaudan No. 45 Sulphuric acid Purified water

6.2 Incompatibilities

None stated.

6.3 Shelf life

30 months.

6.4 Special precautions for storage

Do not store above 25°C

6.5 Nature and contents of container

Collapsible aluminium tube.

Pack size: 15g

6.6 Special precautions for disposal

None

7 MARKETING AUTHORISATION HOLDER

GlaxoSmithKline Consumer Healthcare (UK) Trading Limited,

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

MARKETING AUTHORISATION NUMBER(S)

PL 44673/0104

9


10


DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

1st September 1997

DATE OF REVISION OF THE TEXT

13/04/2016